A key Japanese health ministry advisory panel will discuss on August 28 whether to recommend approval for GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine, known as Arexvy overseas, which would become the first RSV jab in the country if approved. Last…
To read the full story
Related Article
- GSK Seeks Japan Approval of RSV Vaccine
October 24, 2022
REGULATORY
- Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
May 18, 2026
- Japan Eyes June Submission of Immunization Act Bill to Cover Antibody Drugs
May 18, 2026
- Calls Grow for Japan Version of EHDS at Regulatory Reform Panel
May 18, 2026
- Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
May 15, 2026
- MHLW’s Mori Vows to Make Japan Pharma Market “More Attractive”
May 15, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





